---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-25-000017"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:42:18.784106+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Exelixis Q4 2024 rev $567M, GAAP EPS $0.48; FY2024 rev $2.17B, EPS $1.76

## Summary
- Total revenues $566.8M for Q4 2024, up 18% YoY; FY2024 total rev $2.17B, up 18% YoY.
- GAAP diluted EPS $0.48 (Q4 2024) vs $0.27 (Q4 2023); FY2024 $1.76 vs $0.65.
- Non-GAAP diluted EPS $0.55 (Q4 2024) vs $0.33; FY2024 $2.00 vs $0.90.
- Cabozantinib franchise U.S. net product revenues $515M (Q4), $1.81B (FY2024), up from $429M and $1.63B.

## SEC filing metadata
- accession: 0000939767-25-000017
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976725000017/0000939767-25-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976725000017/exel-20250211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-25-000017
- JSON: https://secwatch.observer/filing/0000939767-25-000017.json
- Plain text: https://secwatch.observer/filing/0000939767-25-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.